再鼎醫藥-SB(09688.HK)2021年產品淨收入1.44億美元 研發支出達5.73億美元
格隆匯3月2日丨再鼎醫藥-SB(09688.HK)發佈2021財政年度財務業績公吿,2021年全年的產品淨收入為1.441億美元,2020年同期收入為4900萬美元。其中包括則樂銷售收入9360萬美元(2020年同期為3220萬美元)、愛普盾銷售收入3890萬美元(2020年同期為1640萬美元)、擎樂銷售收入1160萬美元(2020年同期為40萬美元)。集團於2021年第四季度對收入進行了750萬美元的一次性調減,作為對在國家醫保藥品目錄實施前仍在分銷渠道中按2021年價格銷售的則樂的一次性補償。
2021年研究與開發(研發)支出為5.733億美元,2020年同期為2.227億美元。2021年研發支出的增加主要由於八項新籤的許可協議的預付款、正在進行及新啟動的後期臨牀研究的相關費用、增聘研發人員的工資及工資相關開支增加所致。不包括新籤許可協議的預付款在內,2021年核心研發支出為2.52億美元,2020年同期為1.392億美元。
2021年全年,再鼎醫藥虧損淨額為7.045億美元(或普通股東應占每股虧損為7.58美元),2020年同期虧損淨額為2.689億美元(或普通股東應占每股虧損為3.46美元)。虧損淨額的增加主要由於新商務拓展活動的相關開支所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.